Zenas BioPharma, Inc./$ZBIO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Zenas BioPharma, Inc.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
- Ticker
- $ZBIO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 167
- Headquarters
- Waltham, United States
- Website
- zenasbio.com
ZBIO Metrics
BasicAdvanced
$1.9B
-
-$9.05
-1.02
-
Price and volume
Market cap
$1.9B
Beta
-1.02
52-week high
$44.60
52-week low
$13.50
Average daily volume
581K
Financial strength
Current ratio
9.933
Quick ratio
9.783
Long term debt to equity
1.202
Total debt to equity
1.205
Interest coverage (TTM)
-11.29%
Profitability
EBITDA (TTM)
-273.87
Gross margin (TTM)
-21,247.30%
Net profit margin (TTM)
-48,438.40%
Operating margin (TTM)
-27,390.10%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-34.42%
Return on equity (TTM)
-199.04%
Valuation
Price to revenue (TTM)
1,519.157
Price to book
7.28
Price to tangible book (TTM)
7.28
Price to free cash flow (TTM)
-5.221
Free cash flow yield (TTM)
-19.15%
Free cash flow per share (TTM)
-5.438
Growth
Revenue change (TTM)
-93.33%
Earnings per share change (TTM)
70.48%
What the Analysts think about ZBIO
Analyst ratings (Buy, Hold, Sell) for Zenas BioPharma, Inc. stock.
Analyst projections of the future price of Zenas BioPharma, Inc. stock.
Bulls say / Bears say
Phase 3 INDIGO cut the risk of an IgG4-RD flare by 56% versus placebo, and significantly improved remission and other key outcomes. This gives obexelimab a strong late-stage clinical evidence base. (New England Journal of Medicine)
Obexelimab reduced rescue-steroid use and steroid-related toxicity; in the open-label extension, the estimated 12-month probability of remaining flare-free was 93% by investigator and adjudication-committee assessment. These findings support its potential as a longer-term, steroid-sparing treatment. (BioSpace)
The FDA accepted the obexelimab application and set 27 May 2027 as its target decision date. That puts Zenas on a defined path towards a possible first product launch and gives investors a clear regulatory catalyst. (SEC)
Obexelimab reduced flare risk by 56%, below the 87% reduction reported for Uplizna in its separate pivotal trial. The studies were not head-to-head, but the gap raises questions about obexelimab’s differentiation against an established treatment. (Stockopedia)
Hypersensitivity was reported in 16.5% of obexelimab-treated patients versus 11.3% on placebo in INDIGO. Although serious adverse events were less common with obexelimab overall, this higher rate could be a tolerability concern. (New England Journal of Medicine)
Zenas reported a $111.5 million second-quarter net loss and says its runway to the second quarter of 2029 assumes approval-linked funding, including a $75 million royalty payment and a $75 million debt draw. Delayed or denied approval could therefore weaken its funding outlook and increase pressure to raise capital. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
ZBIO Financial Performance
Revenues and expenses
ZBIO Earnings Performance
Company profitability
Upcoming events
No upcoming events
ZBIO News
AllArticlesVideos
Funds containing ZBIO
Fund name | Fund size | $ZBIO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.12% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.12% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.